Navigation Links
Automated 'Artificial Pancreas' Controls Blood Glucose Levels in Diabetes Patients for First Time

- Study Presented at American Diabetes Association Scientific Sessions -

NEW ORLEANS, June 8 /PRNewswire/ -- UC Santa Barbara and Sansum Diabetes Research Institute scientists have demonstrated for the first time that an automated artificial pancreas system (APS) can safely and effectively maintain desired blood glucose levels in patients with type 1 diabetes. The clinical study results will be presented today in a late-breaking poster session(1) at the American Diabetes Association's 69th Scientific Sessions in New Orleans.

The UCSB and Sansum researchers, working with the Schneider Children's Medical Center of Israel, tested an automated insulin delivery system comprising the OmniPod(R) System and the DexCom STS7(R) continuous glucose monitor, linked and controlled through UCSB's artificial pancreas software. The software's insulin delivery algorithm, optimized for each patient, includes a unique safety feature, based on clinical parameters, which prevents insulin-induced low blood glucose levels (hypoglycemia).

Without any outside intervention, the system restored normal blood glucose levels following both induced high levels (hyperglycemia) and unanticipated meals, while avoiding hypoglycemia. This was achieved through the automatic delivery of insulin to correct for the induced high blood glucose levels, and an insulin infusion rate moderated to ensure a smooth return to normal levels and avoid low blood glucose levels.

"This study demonstrates for the first time a completely automated insulin delivery system that frees the patients from controlling their pumps manually, eliminating the question of compliance in treatment," said principal investigator Frank Doyle, Professor of Chemical Engineering at UCSB.

Doyle continued, "We pulled together a talented team of engineers and medical doctors who created the critical element of the artificial pancreas--a unique algorithm that is robust and straightforward to implement. It's become the gold standard." The UCSB APS software platform is also being used by a number of other teams working on the artificial pancreas project, but no other team has advanced yet to wholly-automated clinical trials.

Closed loop trials were performed in four patients for a mean duration of 5 hours (range of 2-7 hours) and included a meal of 30 grams of carbohydrates. The mean Low Blood Glucose Index was 0.02 (range 0-0.06), the mean High Blood Glucose Index was 9 (range 4.2-15), and the median Daily Risk Range was 'low' (range 'low' to 'moderate').

The poster was presented in New Orleans by Matthew Percival of Doyle's research group. Other researchers in the study included Dr. Eyal Dassau, senior investigator, and Dr. Benyamin Grossman, both of Doyle's group; and Sansum's Dr. Lois Jovanovic, CEO and Chief Scientific Officer, and Dr. Howard Zisser, Director of Clinical Research.

The research is part of the artificial pancreas project, which is funded by the Juvenile Diabetes Research Foundation and is being conducted by an international group of diabetes research centers. The project's first goal is to integrate an insulin pump and continuous blood glucose monitor to closely replicate a healthy pancreas for patients with type 1 diabetes--patients whose pancreases no longer produce insulin, which is used by the body to control blood glucose levels. An artificial pancreas will allow for tighter and automated control of blood glucose levels, which would significantly help to avoid the long-term complications of the disease.

UC Santa Barbara is a leading research institution. The two groups at UCSB involved in this study are the Department of Chemical Engineering, in 2007 ranked ninth in the United States and second in the University of California by U.S. News and World Report, and the Biomolecular Science and Engineering Program, which offers a unique interdisciplinary approach to graduate training and research spanning Biochemistry, Molecular Biology, Bioengineering and Biomolecular Materials.

Sansum Diabetes Research Institute is a non-profit research center devoted to the prevention, treatment, and cure of diabetes through research and education. It is best known for its work on methods to detect and chart the progress of diabetes and its expertise in new diabetes technology.

The OmniPod Insulin Management System--the OmniPod insulin pump and its Personal Diabetes Manager, which normally allows the patient to control it--is manufactured and sold by Insulet Corporation (Nasdaq: PODD). The DexCom STS7 continuous glucose monitor is a product of DexCom, Inc.

(1) abstract 3-LB

    Media Contacts:

    Tony Rairden
    UCSB College of Engineering
    (805) 893-4301

    Darcy Keane, Lazar Partners for Insulet

SOURCE UC Santa Barbara Engineering
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. APIC Supports Automated Surveillance Technologies in Prevention of Healthcare-Associated Infections
2. iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
3. Organizations Have Federal Government Tax Incentives to Purchase Remstar Automated Systems for 2009
4. Automated Calls May Help Doctors Monitor Patients
5. Childrens Hospital of Wisconsin Extends Real-Time Asset Tracking and Automated Charge Capture to their New Patient Pavilion
6. UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
7. NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
8. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
9. Kirby Lesters New KL30: Fully Automated, Compact System for a Fraction of the Cost of a Robotic Dispenser
10. Automated screening process may eventually reduce additional breast cancer surgeries
11. An Evolution in Automated CO2 Laser Surgery
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... discuss bioavailability and the need to integrate dose form selection in early phase ... OBN, the membership organization supporting and bringing together the UK’s emerging life sciences ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... and wellness consultation, has collaborated with Women’s Web – an online resource ... on topics on mental and emotional well-being relationship, life balance, stress, professional ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Finnleo, a ... Christmas Eve on several models of traditional and far-infrared saunas. , For ... Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European Grade ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed ... on behalf of a home health care worker who provided companionship services for the ... care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: